| Autor: |
Anne Zaremba, Rafaela Kramer, Viola De Temple, Stefanie Bertram, Martin Salzmann, Anja Gesierich, Lydia Reinhardt, Barouyr Baroudjian, Michael M. Sachse, Gunhild Mechtersheimer, Douglas B. Johnson, Alison M. Weppler, Lavinia Spain, Carmen Loquai, Milena Dudda, Claudia Pföhler, Adriana Hepner, Georgina V. Long, Alexander M. Menzies, Matteo S. Carlino, Céleste Lebbé, Tomohiro Enokida, Makoto Tahara, Paul J. Bröckelmann, Thomas Eigentler, Katharina C. Kähler, Ralf Gutzmer, Carola Berking, Selma Ugurel, Nadine Stadtler, Antje Sucker, Jürgen C. Becker, Elisabeth Livingstone, Friedegund Meier, Jessica C. Hassel, Dirk Schadendorf, Maher Hanoun, Lucie Heinzerling, Lisa Zimmer |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Frontiers in Oncology, Vol 11 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2234-943X |
| DOI: |
10.3389/fonc.2021.765608 |
| Popis: |
IntroductionImmune checkpoint inhibitors (ICI) are increasingly being used to treat numerous cancer types. Together with improved recognition of toxicities, this has led to more frequent identification of rare immune-related adverse events (irAE), for which specific treatment strategies are needed. Neutropenia is a rare hematological irAE that has a potential for a high mortality rate because of its associated risk of sepsis. Prompt recognition and timely treatment of this life-threatening irAE are therefore critical to the outcome of patients with immune-related neutropenia.MethodsThis multicenter international retrospective study was conducted at 17 melanoma centers to evaluate the clinical characteristics, diagnostics, treatment, and outcomes of melanoma patients with grade 4 neutropenia ( |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
